Carl Regillo, Hawaiian Eye and Retina 2023: Vascular endothelial growth factor inhibitors – real-world versus clinical trial outcomes
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about the problems with the clinical utility of vascular endothelial growth factor inhibitors and the issues around durability and ensuring good outcomes in real-world settings, as opposed to just in clinical trials.
- How do age-related macular degeneration (AMD) outcomes in real-world settings with vascular endothelial growth factor (VEGF) inhibitors differ from those in clinical trials, and what is the reason for this? (0:23)
- What other factors limit the clinical utility of VEGF inhibitors in the treatment of AMD? (1:48)
The presentation entitled, New and Emerging Neovascular AMD Treatments was presented at the Hawaiian Eye and Retina 2023 meeting, 14–20 January, 2023.
Disclosures: Carl Regillo has served as a consultant for 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, Curacle, Eyepoint, Genentech, Graybug, Iveric, Janssen, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Ray, RegenXBio, Stealth, Thea, Zeiss, and has received grant/research support from Adverum, Allergan, Annexon, Apellis, Astellis, Curacle, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of Hawaiian Eye and Retina 2023.
Click here for more content from Dr Carl Regillo.
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!